InvestSMART

Oncosil Medical Limited (ASX:OSL)

ALERT: Price-sensitive ASX Announcement for OSL
Current share price for OSL : $1.550 0.85 (121.43%)+
Announcement
Release
12 Feb 2026 9:17AM
Price at Release
$0.700
Full Release
download
Summary
OncoSil Medical Limited announced a strategic update to their CEO remuneration plan aiming to enhance executive alignment with shareholders. CEO Nigel Lange has agreed to a 10% reduction in fixed remuneration, with the foregone amount replaced by shares issued at a substantial premium. These shares are subject to a 12-month escrow and will require shareholder approval. This adjustment is part of a broader effort to maintain cost discipline and preserve strategic momentum, aligning executive incentives with shareholder value creation. Lange’s terms include a €260,000 annual remuneration with incentives linked to company performance, reinforcing the firm's commitment to developing innovative treatments for pancreatic cancer.
Key Points
  • OncoSil Medical Ltd announced changes to CEO remuneration to enhance executive alignment with shareholders.
  • CEO Nigel Lange agreed to a 10% reduction in fixed remuneration, replacing this with shares issued at a 121% premium.
  • The shares are subject to a 12-month escrow and will require shareholder approval.
  • Lange's employment terms include a fixed annual remuneration of €260,000, with 10% settled in shares.
  • Eligible for a short-term incentive of up to 35% and a long-term incentive of up to 35% of base salary.
  • The changes aim to preserve strategic momentum while maintaining a disciplined cost structure.
  • OncoSil focuses on localised treatments for unresectable locally advanced pancreatic cancer using Phosphorous-32 Microparticles.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.